Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2022 Financial Results
Neurocrine Biosciences (Nasdaq: NBIX) announced its first quarter 2022 financial results conference call and webcast scheduled for May 4, 2022, at 5:00 a.m. PT (8:00 a.m. ET). The Q1 2022 press release will be made available at 4:30 a.m. PT (7:30 a.m. ET) on the same day. Investors can join via a domestic dial-in number (800-895-3361) or international dial-in number (785-424-1062), using the conference ID: NBIX. The webcast link will be accessible on the Neurocrine Biosciences website, with a replay available for one month.
- Scheduled conference call for Q1 2022 could indicate good communication with investors.
- Diverse portfolio including FDA-approved treatments and numerous mid-to-late-stage clinical programs.
- None.
Conference Call and Webcast Scheduled for Wednesday, May 4
SAN DIEGO, April 13, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2022 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on May 4, 2022.
The schedule for the press release and conference call / webcast is as follows:
• Q1 2022 Press Release: | May 4, 2022 at 4:30 a.m. PT / 7:30 a.m. ET |
• Q1 2022 Conference Call: | May 4, 2022 at 5:00 a.m. PT / 8:00 a.m. ET |
• Domestic Dial-In Number: | 800-895-3361 |
• International Dial-In Number: | 785-424-1062 |
• Conference ID: | NBIX |
The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, as well as over a dozen mid-to-late-stage clinical programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-first-quarter-2022-financial-results-301525233.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
When is Neurocrine Biosciences' Q1 2022 conference call scheduled?
How can I access the Q1 2022 financial results from Neurocrine Biosciences?
What is the conference ID for Neurocrine Biosciences' call?
What are the dial-in numbers for the Neurocrine Biosciences Q1 2022 call?
